These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17632196)

  • 1. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
    Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
    Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
    Wang S; Nie J; Wang Y
    Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
    Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
    Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
    Rollman E; Hinkula J; Arteaga J; Zuber B; Kjerrström A; Liu M; Wahren B; Ljungberg K
    Gene Ther; 2004 Jul; 11(14):1146-54. PubMed ID: 15103320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
    Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
    J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and partial characterization of R5, R5X4, and X4 HIV-1 subtype C envelope glycoproteins expressed in insect cells.
    Nkosi SP; Huismans H; Papathanasopoulos MA
    J Med Virol; 2005 Aug; 76(4):459-63. PubMed ID: 15977243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
    Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype.
    Walker PR; Cilliers T; Choge IA; Taylor N; Cohen SS; Morris L
    J Med Virol; 2006 Oct; 78(10):1262-8. PubMed ID: 16927278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response.
    Ho J; Uger RA; Zwick MB; Luscher MA; Barber BH; MacDonald KS
    Vaccine; 2005 Feb; 23(13):1559-73. PubMed ID: 15694508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.
    Nyambi P; Burda S; Urbanski M; Heyndrickx L; Janssens W; Vanham G; Nadas A
    AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1507-19. PubMed ID: 19018670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa.
    Wilkinson E; Engelbrecht S
    Infect Genet Evol; 2009 Sep; 9(5):840-6. PubMed ID: 19446657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
    Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
    Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.
    Chong H; Hong K; Zhang C; Nie J; Song A; Kong W; Wang Y
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):535-43. PubMed ID: 18209676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.